Catalyst Successfully Completes First Subcutaneous Factor IX Dosing Group in Hemophilia B Clinical Trial
Catalyst Biosciences recently announced that its collaborator, ISU Abixs, has completed dosing of the first subcutaneous cohort in an ongoing Phase…